Evofem announced today that it has entered into a strategic alliance with WomanCare Global. Through this alliance, WomanCare Global will provide sales, marketing and global distribution for a selection of Evofem's products, including Softcup™ and Amphora®. Additionally, Saundra Pelletier , founding CEO of WomanCare Global, has been named the new CEO of Evofem Inc.
Amphora, a vaginal gel approved by the FDA in 2004 as a lubricant, is currently undergoing the largest global clinical trial to date of a non-hormonal contraceptive vaginal gel. Through various studies, Amphora has shown potential to be effective in protecting against sexually transmitted infections (STIs) including HIV. Softcup is a personal care alternative to tampons and sanitary pads that can be worn for up to 12 hours. It's body-friendly, in both disposable and reusable options, with no drying cotton or rayon fibers and no link to Toxic Shock Syndrome (TSS).
"Our strategic alliance with WomanCare Global is a momentous achievement for Evofem," said Joseph Pike , Evofem LLC's Chief Executive Officer. "Having developed a distribution supply chain into over 100 countries, WomanCare Global operates as a sustainable not-for-profit that will allow us to provide our products and services to women and girls throughout the world, especially to those who live in areas where their reproductive healthcare needs are underserved."
"We are so pleased to partner with Evofem to create global access to Softcup and contribute to the commercialization plans for Amphora," said WomanCare Global CEO Saundra Pelletier . "These exciting reproductive health products offer women and girls with an innovative, new contraceptive choice and a safe way to manage their menses."
Study finds oral contraceptives may alter glycemic response in women using androgenic pills